NEW YORK--(EON: Enhanced Online News)--Levi & Korsinsky announces it has commenced an investigation of Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) (“Anthera Pharmaceuticals”) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
“the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.”
On November 10, 2016, Anthera announced that “the CHABLIS-SC1 clinical trial with blisibimod for the treatment of systemic lupus erythematosus (SLE) failed to meet its primary endpoint based upon the SLE Responder Index-6 (SRI-6) at 52 weeks.” Then on December 27, 2016, Anthera announced that its SOLUTION Phase 3 Study for liprotamase also failed to meet its primary endpoint. The Company announced it would conduct a new study of liprotamase. During this time, shares of Anthera fell 73%, from a close of $2.78 per share on November 9, 2016 to a close of $0.74 per share on December 28, 2016. To obtain additional information, go to:
or contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.